J. Safra Sarasin Holding AG reduced its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 93.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,503 shares of the company’s stock after selling 138,509 shares during the period. J. Safra Sarasin Holding AG’s holdings in Zoetis were worth $1,123,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Global Wealth Strategies & Associates bought a new position in shares of Zoetis in the 4th quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new position in Zoetis in the fourth quarter worth about $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis during the fourth quarter worth approximately $30,000. Root Financial Partners LLC increased its stake in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the third quarter valued at approximately $31,000. 92.80% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
ZTS has been the subject of several analyst reports. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. HSBC cut their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Morgan Stanley restated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. Barclays lowered their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $123.46.
Trending Headlines about Zoetis
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Zoetis announced a deal to acquire VitalRADS, a provider of veterinary imaging services, which could support growth in its animal-health business by expanding diagnostic capabilities. Zoetis to acquire VitalRADS, a provider of veterinary imaging services
- Neutral Sentiment: Several firms, including Rosen, Glancy Prongay Wolke & Rotter, the Gross Law Firm, Levi & Korsinsky, and others, issued reminders about the Zoetis securities class action and the upcoming deadline, increasing the amount of negative press but not adding new case details. Pomerantz law firm investor alert
- Negative Sentiment: The class action alleges Zoetis and certain executives made misleading statements about companion-animal product performance while safety concerns and competitive losses were building, which is weighing on investor sentiment. ZTS shareholder alert
- Negative Sentiment: The stock also appears to be reflecting a weaker trading tone after recent earnings disappointment, with Zoetis having previously missed analyst estimates on EPS and revenue, adding to concerns about near-term fundamentals. Zoetis stock dips while market gains: key facts
Insider Activity
In related news, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders purchased 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by company insiders.
Zoetis Trading Down 1.7%
ZTS opened at $74.08 on Wednesday. The stock has a market cap of $31.06 billion, a price-to-earnings ratio of 12.29, a P/E/G ratio of 1.18 and a beta of 0.75. The stock’s 50 day moving average price is $78.40 and its 200-day moving average price is $106.94. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the business posted $1.48 earnings per share. Zoetis’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.
Zoetis Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.
Zoetis Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Read More
- Five stocks we like better than Zoetis
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
